Global Markets for Diabetes Therapeutics and Diagnostics

Report Code: HLC029F

Publish Date: Sep 2023

Publisher: BCC Publishing

Category: Health Maintenance

Download Report Overview

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for diabetes therapeutics and diagnostics is estimated to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.

Report Includes

  • 162 data tables and 63 additional tables
  • An up-to-date overview and analysis of the global markets for diabetes therapeutics and diagnostics
  • Analyses of the global market trends, with market revenue (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Understanding of the upcoming market potential for AI in diabetic mellitus management with an emphasis on new products and solutions/platform technologies, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size and revenue forecast for the global diabetes therapeutics and diagnostics market, and corresponding market share analysis based on product type, end user, and geographical region
  • In-depth information (facts and figures) on major market dynamics, opportunities and gaps estimating the demand, technology adaptations in diabetes care, industry developments, regulatory dynamics, and the COVID-19 impact on the progress of this market
  • Identification of the companies best positioned to meet this demand owing to or in conjunction with their proprietary technologies, product launches, and other strategic advantages
  • Review of key patent grants and patent applications on diabetes therapeutics and diagnostics, and emerging technologies and new developments in this market
  • Analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
  • Company profiles of the leading global players, including Novo Nordisk, Sanofi S.A., Lilly, Takeda, Danaher Corp., and AstraZeneca

Report Scope

This report discusses the implications of the trends mentioned above in the context of the current size and growth of the diabetes market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug and device categories, and there are country-level breakdowns of the diabetes market.

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2022 as the base year, 2023 and forecast through year-end 2028.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $97.3 billion
Market size forecast $132.0 billion
Growth rate CAGR of 5.2% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Product Group, End-User, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW).
Countries covered U.S., Canada, Mexico, France, Germany, U.K., Italy, Spain, China, India, and Japan
Key Market Drivers
  • Increasing incidence & prevalence of diabetes.
  • Changing lifestyle habits.
  • Growing geriatric population.
  • Increase in prevalence of chronic diseases.
Companies studied
77 ELEKTRONIKA KFT.ABBOTT
ALTUCELL INC.ASCENSIA DIABETES CARE HOLDINGS AG
ASTRAZENECAB. BRAUN SE
BIOCONBOEHRINGER INGELHEIM INTERNATIONAL GMBH
DANAHER CORP.DEXCOM INC.
EMBECTA CORP.INSULET CORP.
JOHNSON & JOHNSON SERVICES INC.LIFESCAN IP HOLDINGS LLC.
LILLYMEDTRONIC
MENARINI GROUP (A. MENARINI DIAGNOSTICS S.R.L)MERCK & CO. INC.
MERCK KGAANEXTCELL PHARMA AB
NIPRONOVA BIOMEDICAL
NOVARTIS AGNOVO NORDISK A/S
F. HOFFMANN-LA ROCHE LTD.SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.TANDEM DIABETES CARE INC.
TERUMO CORP.YPSOMED AG
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Frequently Asked Questions (FAQs)

The diabetes therapeutics and diagnosticsmarket is projected to grow from $97.2 billion in 2022 to $132.0 billion in 2028 at a compound annual growth rate (CAGR) of 5.2% during the forecast period.
The key factors driving the growth of the diabetes therapeutics and diagnostics market include Increasing incidence & prevalence of diabetes, technological advancements in diabetes therapeutics and diagnostics, and strategic initiatives by major players in developed nations are propelling the growth of this market.
The diabetes therapeutics and diagnostics market is segmented based on product group, end-user, and region.
The Diabetes Therapeutics segment will dominate the market by the end of 2028.
Key companies in the market include Novo Nordisk A/S, Lilly, Boehringer Ingelheim International GmbH, AstraZeneca, Abbott., Merck & Co., Inc., Sanofi, Dexcom, Inc., Medtronic, and Others.

Analyst Credentials

Bejini Sandeep Kumar– Assistant Manager - Life Sciences Research
Sandeep Kumar has over 11 years of experience in pharmaceutical and medical equipment research and consulting. With expertise lying in business research studies, such as industry analysis, strategic and financial analysis, opportunity assessment and competitor intelligence. Sandeep has extensive experience in market research and analysis, specializing in healthcare, medical devices, biotechnology, healthcare IT, pharmaceuticals, and others. He holds a bachelor’s degree in Biotechnology and a Post Graduate degree in Business Management from Liverpool John Moores University (LJMU).

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
. Title/Chapter NamePagesPrice Member Price
Full Report: Global Markets for Diabetes Therapeutics and Diagnostics336 $4,650 Free
Chapter- 1: Introduction7Free DownloadFree
Chapter- 2: Summary and Highlights6$250Free
Chapter- 3: Market Overview17$237Free
Chapter- 4: Global Market for Diabetes Therapeutics 29$405Free
Chapter- 5: Global Market for Diabetes Monitoring Devices and Accessories22$307Free
Chapter- 6: Global Market for Diabetes Delivery Devices by Type39$545Free
Chapter- 7: Global Market for Diabetes Therapeutics and Diagnostics by End User3$42Free
Chapter- 8: Global Market for Diabetes Therapeutics and Diagnostics by Region61$852Free
Chapter- 9: Sustainability in the Market for Diabetes Therapeutics and Diagnostics: An ESG Perspective5$70Free
Chapter- 10: Emerging Technologies5$70Free
Chapter- 11: M&As and Venture Funding Outlook in the Market 23$321Free
Chapter- 12: Competitive Landscape15$209Free
Chapter- 13: Company Profiles101$1,410Free
Chapter- 14: Appendix3$42Free
Published - Sep-2016| Analyst - Paul Evers| Code - HLC029E

Report Highlights

The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.

Report Includes

  • An overview of the global market for diabetes
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
  • Analysis of the devices and instruments used in the diagnosis and monitoring of diabetes
  • A close look at major forces contributing to the vigorous growth of the diabetes market
  • Evaluation of other factors influencing the market such as health care policies, demographics, and the wider economic environment
  • Discussion covering companies in the relevant pharmaceutical and medical industries through company profiles of many leading players in the field

Published - Jan-2013| Analyst - Paul Evers| Code - HLC029D

Report Highlights

The global market for diabetes therapeutics and diagnostics was valued at $110 billion in 2011 and should reach nearly $118.7 billion in 2012.  Total market value is expected to reach nearly $157 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5.7%.

Published - Jun-2010| Analyst - Paul Evers| Code - HLC029C

Report Highlights

  • The global market for therapeutic and diagnostic products for diabetes is valued at $38 billion in 2010. This market is expected to grow at a compound annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
  • Insulin products, including administration devices, are worth an estimated $16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a 6.1% compound annual growth rate (CAGR). 
  • Oral hypoglycemic drugs are expected to achieve the highestcompound annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to $15.1 billion in 2015.

Published - Mar-2008| Analyst - Ann Zhai| Code - HLC029B

Report Highlights

  • The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%.
  • The global diabetes market will become one of the largest healthcare markets over the next five years, due in large part to the epidemic explosion of the type II diabetes population.
  • Over the next five years, market leaders will overcome technology barriers to bring non-invasive, insulin-dependent products to the market.
Published - Oct-2002| Analyst - Amy Adams| Code - HLC029A

Report Highlights

  • The total market for diabetes drugs and devices is estimated at $18 billion in 2002. Growing at an average annual rate (AAGR) of 11.5%, the market is expected to exceed $30.7 billion in 2007.
  • Drug sales in 2002 are expected to be $12.5 billion, increasing to almost $21 billion by 2007 at an AAGR of 10.3%.
  • Insulin was 33% of the market in 2000 and is expected to hold on to that share.
  • Sulfanylureas and biguanides are expected to lose considerable market share to generics, newer classes of drugs, and to the extremely popular thiazolidinediones.
  • The two major diabetes medical devices are glucose monitors and insulin pumps. Glucose monitors are expected to rise at an AAGR of 13.7% to $8 billion by 2007. Insulin pumps are expected to grow to $1.8 billion by 2007 at an AAGR of 18.7%.

Related Reports

Global Markets for Generic Drugs

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM009K

The global market for generic drugs is expected to grow from $435.3 billion in 2023 and projected to reach $655.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2028.

Hemoglobin A1c Testing Devices and Kits Market

Published - Oct 2023 | Publisher - Partha Sarathi Das | Code - MDS095A

The global market for hemoglobin A1c testing devices and kits is estimated to increase from $2.1 billion in 2023 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 9.2% from 2023 through 2028.

Global Market for Stem Cells

Published - Apr 2023 | Publisher - BCC Publishing | Code - BIO035H

The global stem cell market reached $32.1 billion in 2022 and should reach $65.6 billion by 2027, with a compound annual growth rate (CAGR) of 15.3% during the forecast period of 2022-2027.

Type 2 Diabetes Treatment: Global Market Outlook

Published - Jan 2023 | Publisher - BCC Publishing | Code - HLC287A

The goal is to provide an up-to-date analysis of the global type 2 diabetes treatment market and future opportunities in the market. It presents a thorough and up-to-date global assessment of the market and business of the type 2 diabetes treatment. This will help industry participants, suppliers, government bodies, associations, and customers make the informed decisions needed to compete and succeed in the marketplace. The scope of the study includes the various types of medicines involved in type 2 diabetes treatment and management. Blood glucose monitoring, diagnostic systems and devices, and insulin-delivery devices used in the treatment of type 2 diabetes, however, have been excluded from this study.

Recent Reports

Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets

Published - Aug 2024 | Publisher - BCC Publishing | Code - HLC176E

The global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2029.

Routine Health Screening Market

Published - Jul 2024 | Publisher - BCC Publishing | Code - HLC299A

The global market for routine health screening is expected to grow from $59.7 billion in 2024 and is projected to reach $82.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029.

Elder Care Services and Assistive Devices: Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - HLC062E

The global market for elder care services and assistive devices is expected to grow from $868.2 billion in 2024 and is projected to reach $1.1 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 5.8% during the forecast period of 2024 to 2029.

Direct-to-Consumer Testing Industry: Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - HLC269B

The global market for direct-to-consumer (DTC) testing is estimated to increase from $1.6 billion in 2023 to reach $3.2 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.

Health and Medical Insurance Providers: Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - HLC212B

The global market for health and medical insurance providers is expected to grow from $2.2 trillion in 2023 to $3.4 trillion by the end of 2028, at a compound annual growth rate (CAGR) of 8.9% during the forecast period of 2023 to 2028.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Global Markets for Diabetes Therapeutics and Diagnostics
Sample Report